Atopic dermatitis: tacrolimus vs. topical corticosteroid use

Langa, Y; Merwe, E Van der

doi:10.1080/20786204.2011.10874111

Cited by 3 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, in a 4-year followup study of children and adult patients with AD treated with 0.1% tacrolimus, 75% of patients and 76% of investigators expressed high satisfaction with the treatment [66]. In studies comparing tacrolimus 0.1% and TCS, efficacy results have favored tacrolimus although comparison of their impact on quality of life is less clear-cut [67,68]. In a study comparing pimecrolimus 1% cream and tacrolimus 0.03% ointment in pediatric patients with AD, although efficacy was similar between treatments, a greater proportion of patients (or caregivers, in the case of pediatric patients unable to answer questions themselves) rated pimecrolimus as very good or excellent compared with tacrolimus for several aspects, including suitability for use on sensitive facial skin; non-sticky feel; ease of application; and ease of rub-in [69].…”

Section: Anti-inflammatory Treatmentmentioning

confidence: 99%

Practical Recommendations for the Topical Treatment of Atopic Dermatitis in South and East Asia

Luk

Hon

Dizon

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction There is some evidence to suggest that the prevalence of atopic dermatitis (AD) in Asia is rising. We have therefore developed an algorithm for the topical treatment of AD throughout South and East Asia for use by primary care physicians, pediatricians and dermatologists. Methods Nine AD experts from South and East Asia and one from Europe developed the algorithm based upon treatment guidelines, relevant literature and local treatment practices. The algorithm outlines current best practice for the use of emollients, topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI), with the intention of simplifying the treatment regimen of mild-to-moderate AD in South and East Asia. Results Patients with AD should bathe and cleanse affected skin to remove crusts and scales daily. Emollients should also be applied daily as a maintenance treatment. When selecting appropriate topical anti-inflammatory treatment for AD flares, several factors should be taken into consideration, including the patient’s age, attitude to treatment options and site of AD lesions. Given the concerns regarding the risk of skin atrophy with use of TCS, a TCI should be used to treat AD lesions in sensitive skin areas: pimecrolimus is recommended for mild-to-moderate AD in these locations, while tacrolimus should be considered for moderate and severe cases. Either pimecrolimus or tacrolimus is recommended for flares in other, non-sensitive body locations. A proactive or intermittent maintenance treatment strategy involving regular emollient use and twice-weekly application of a TCI to previously affected areas is encouraged to reduce the risk of flares. Conclusions The algorithm proposed here is intended to simplify the topical treatment of mild-to-moderate AD in daily practice in South and East Asian countries.

show abstract

Section: Anti-inflammatory Treatmentmentioning

confidence: 99%

Practical Recommendations for the Topical Treatment of Atopic Dermatitis in South and East Asia

Luk

Hon

Dizon

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…By adopting an alpha level of (0.05) a beta of (0.2) i.e. power=80% and a critical z value of (1.96) calculated based on the results of a previous study (12) , the predicted sample size (n) was a total of (62) cases (31 cases per group). Sample size was increased by 20 % to compensate for possible dropouts during follow-up intervals to be (76) cases (i.e 38 cases per group).…”

Section: Type Of Study: a Randomized Controlled Clinical Trialmentioning

confidence: 99%

Topical administration of tacrolimus and systemic corticosteroids in treatment of oral and nasal mucous membrane pemphigoid in a sample of Egyptian population: A randomized control Clinical trial

Hamed

elmoniem

Elsayed

et al. 2023

Egyptian Dental Journal

View full text Add to dashboard Cite

Objectives:The study aimed to evaluate the effect of topical tacrolimus as adjunctive to systemic corticosteroids in treatment of mucous membrane pemphigoid. Material & Methods:The present study was conducted on 76 patients with severe mucous membrane pemphigoid according to chan et al classification. Patients were allocated (1:1) to a group. Group A (control group) patients treated with 40 mg systemic corticosteroids alone and group B (Study group) patients were treated with 40 mg systemic corticosteroids and topical tacrolimus as adjunctive to corticosteroids. Total ulcers score (site, activity, and pain score) was recorded in both groups on weekly basis till the full recovery of oral, oropharyngeal and nasal lesions.Results: Both treatment regimen had shown a significant improvement in total ulcer scores with (P<0.001) of the oral and nasal lesion scores from the beginning of the study to its end, but the study group (combination of corticosteroids and tacrolimus) revealed significant decrease (P<0.001) compared to the study (corticosteroid alone) group. Conclusion:The use of topical tacrolimus as adjunctive to systemic corticosteroids could improve healing and total ulcer score in severe cases of mucous membrane pemphigoid than solo treatment with systemic corticosteroids

show abstract

“…Dermatitis, on the other hand, is a medical condition associated with reddening, swelling, and soreness of the skin, with small blisters resulting from direct irritation of the skin by an external agent or an allergic reaction. 4…”

mentioning

confidence: 99%

An Overview of Atopic Dermatitis with a Focus on Nano-Interventions

2019

View full text Add to dashboard Cite

With nano-based products becoming ubiquitous across all therapeutic areas, especially the area of skin care, it has become imperative to review the correlation between the unmet needs and the pipelines of available products. Atopic dermatitis (AD) is prevalent across different regions of the world with an incidence rate varying from 15–30% in children and adults. The pathogenesis of AD is a complex interplay between defects in skin barrier function, environmental and infectious agents, and immune abnormalities. Furthermore, although the role of reactive oxygen species has been studied in AD and other skin diseases to some extent, its importance in AD has rarely been investigated. The limitations associated with the use of currently available therapies like topical corticosteroids (first-line) and/or topical calcineurin inhibitors, and the use of other over-the-counter products to manage the sleep disturbances and skin infections, create a need for other innovative solutions. Nano-intervention forms a large panel of delivery aids, including lipidic and polymeric nanoparticles, liposomes, silica nanoparticles, hydrogels, and several other delivery systems. These interventions are mainly designed to achieve higher drug encapsulation, greater stability, and higher skin permeation. This review aims to give an overview of the epidemiology of AD, the pathogenic events, and the challenges present with currently available therapies. There is a special focus on the recent developments in various nanocarrier technologies for treating AD.

show abstract

Atopic dermatitis: tacrolimus vs. topical corticosteroid use

Cited by 3 publications

References 10 publications

Practical Recommendations for the Topical Treatment of Atopic Dermatitis in South and East Asia

Practical Recommendations for the Topical Treatment of Atopic Dermatitis in South and East Asia

Topical administration of tacrolimus and systemic corticosteroids in treatment of oral and nasal mucous membrane pemphigoid in a sample of Egyptian population: A randomized control Clinical trial

An Overview of Atopic Dermatitis with a Focus on Nano-Interventions

Contact Info

Product

Resources

About